ArticleJournal of clinical laboratory analysis2022
Frequency of serological markers of rheumatoid arthritis in patients with IgA anti-β2 glycoprotein I antibodies.
Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Molecular mimicry in the pathogenesis of autoimmune rheumatic diseases.Journal of translational autoimmunity · 2025Review
- Frequency of serological markers of rheumatoid arthritis in patients with IgA anti-β2 glycoprotein I antibodies.Journal of clinical laboratory analysis · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo determine the frequency of serological markers of RA in patients with anti-β2 glycoprotein I antibodies (aβ2GPI) of IgA isotype. MATERIAL AND
methodsA retrospective study was conducted on 67 patients with aβ2GPI-IgA. Ninety healthy blood donors (HBD) were used as a control group. IgG anti-cyclic citrullinated peptides antibodies (CCP-Ab) and rheumatoid factors (RF) IgG, IgA, and IgM were detected by enzyme-linked immunosorbent assay (ELISA).
resultsSeventeen patients and eight HBD had CCP-Ab and/or RF (25.4% vs. 8.9%, p = 0.005, CI 95% [14.95; 35.79], odds ratio = 3.5). The frequency of CCP-Ab was significantly higher in patients than in healthy subjects (14.9% vs. 3.3%, p = 0.009). IgA isotype of RF was significantly higher in patients than in controls (7.5% vs. 0%, p = 0.02). In male patients, CCP-Ab and/or RF were more frequent than in healthy male subjects (37.5% vs. 11.8%, p = 0.02). In patients, no correlation was found between the levels of aβ2GPI-IgA and CCP-Ab (r = 0.082, p = 0.51). There was no correlation between the level aβ2GPI-IgA and the level of the isotypes of RF (IgG, IgA, and IgM) in patients (r = 0.1, p = 0.37; r = 0.17, p = 0.17 and r = 0.07, p = 0.59 respectively).
conclusionFrequencies of CCP-Ab and RF are high in patients with aβ2GPI-IgA suggesting that these patients are susceptible to developing RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.